Safety and Effectiveness of Ombitasvir/Paritaprevir/Ritonavir +/- Dasabuvir +/- Ribavirin in HCV Genotype 1-and 4-Infected Patients Treated for 12 Weeks: Real-World Evidence From a Global Multicountry Postmarketing Observational Study

Ferenci Peter; Buggisch Peter; Norris Suzanne; Kleine Henning; Charafeddine Mariem; Crown Eric; Bondin Mark; Flisiak Robert

首页> 外文期刊>Hepatology: Official Journal of the American Association for the Study of Liver Diseases >Safety and Effectiveness of Ombitasvir/Paritaprevir/Ritonavir +/- Dasabuvir +/- Ribavirin in HCV Genotype 1-and 4-Infected Patients Treated for 12 Weeks: Real-World Evidence From a Global Multicountry Postmarketing Observational Study

【24h】

Safety and Effectiveness of Ombitasvir/Paritaprevir/Ritonavir +/- Dasabuvir +/- Ribavirin in HCV Genotype 1-and 4-Infected Patients Treated for 12 Weeks: Real-World Evidence From a Global Multicountry Postmarketing Observational Study

机译：HCV基因型1-and 4感染患者在治疗12周的HCV基因型1和4感染患者中的安全性和有效性：来自全球多月经的观察研究的现实世界证据

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Hepatology: Official Journal of the American Association for the Study of Liver Diseases》 |2017年第1期|共2页
作者
Ferenci Peter; Buggisch Peter; Norris Suzanne; Kleine Henning; Charafeddine Mariem; Crown Eric; Bondin Mark; Flisiak Robert;
展开▼
作者单位

Med Univ Vienna Vienna Austria;

IFI Inst Interdisziplinare Med Hamburg Germany;

Trinity Coll Dublin Sch Med Dublin Ireland;

AbbVie Deutschland GmbH &

Co KG Wiesbaden Germany;

AbbVie N Chicago IL USA;

AbbVie N Chicago IL USA;

AbbVie N Chicago IL USA;

Med Univ Bialystok Dept Infect Dis &

Hepatol Bialystok Poland;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类消化系及腹部疾病;
关键词

相似文献

外文文献
中文文献
专利

1. Safety and Effectiveness of Ombitasvir/Paritaprevir/Ritonavir +/- Dasabuvir +/- Ribavirin in HCV Genotype 1-and 4-Infected Patients Treated for 12 Weeks: Real-World Evidence From a Global Multicountry Postmarketing Observational Study [J] . Ferenci Peter, Buggisch Peter, Norris Suzanne, Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2017,第Suppla1期

机译：HCV基因型1-and 4感染患者在治疗12周的HCV基因型1和4感染患者中的安全性和有效性：来自全球多月经的观察研究的现实世界证据
2. Effectiveness and Safety of Ombitasvir-Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin for HCV Genotype 1 Infection for 12 Weeks Under Routine Clinical Practice [J] . Chamorro-de-Vega Esther, Gimenez-Manzorro Alvaro, Guadalupe Rodriguez-Gonzalez Carmen, The annals of pharmacotherapy . 2016,第11期

机译：在常规临床实践中，Ombitasvir-Paritaprevir / Ritonavir和Dasabuvir联合或不联合利巴韦林对HCV基因型1感染的有效性和安全性为期12周
3. Real-world efficacy and safety of ombitasvir/paritaprevir/ritonavir +/- dasabuvir +/- ribavirin in patients with HCV genotype 1 and 4 infection, final results of the AMBER study [J] . Flisiak Robert, Janczewska Ewa, Wawrzynowicz-Syczewska Marta, Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2016,第S1期

机译：IMBITASVIR / PARITAPREVIR / Ritonavir +/- Dasabuvir +/-利巴韦林在HCV基因型1和4感染患者中的真实世界疗效和安全性，琥珀色研究的最终结果
4. Real-world efficacy safety and clinical outcomes of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: The Turkey experience experience [O] . Bilgehan Aygen, Neşe Demirtürk, Orhan Yıldız, 2020

机译：ombitasvir / paritaprevir / ritonavir±达沙布韦±利巴韦林联合疗法对1型或4型肝炎病毒患者的真实疗效安全性和临床结果：土耳其经验
5. PGI21 Cost-effectiveness of treating Hepatitis C Virus (HCV) Genotype 1 (GT1) patients with abbvie 3D (Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir) +/- ribavirin compared to harvoni (Sofosbuvir/Ledipasvir) in the United States [O] . Johnson S., Parise H., Virabhak S., 2015

机译：PGI21与美国的harvoni（Sofosbuvir / Ledipasvir）相比，用abbvie 3D（Paritaprevir / Ritonavir / Ombitasvir和Dasabuvir）+/-利巴韦林治疗丙型肝炎病毒（HCV）基因1型（GT1）患者的成本效益

Safety and Effectiveness of Ombitasvir/Paritaprevir/Ritonavir +/- Dasabuvir +/- Ribavirin in HCV Genotype 1-and 4-Infected Patients Treated for 12 Weeks: Real-World Evidence From a Global Multicountry Postmarketing Observational Study

著录项

相似文献

相关主题

期刊订阅